SLC2A13

Summary

SLC2A13 (solute carrier family 2 member 13, HGNC:15956) is a protein-coding gene on chromosome 12q12, encoding Proton myo-inositol cotransporter (Q96QE2). H(+)-myo-inositol cotransporter.

Enables ATPase binding activity; myo-inositol:proton symporter activity; and protease binding activity. Involved in myo-inositol transport and positive regulation of amyloid-beta formation. Located in cell body; cell projection; and plasma membrane.

Source: NCBI Gene 114134 — RefSeq curated summary.

At a glance

• GWAS associations: 12
• Clinical variants (ClinVar): 37 total
• MANE Select transcript: NM_052885

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:15956
Approved symbol	SLC2A13
Name	solute carrier family 2 member 13
Location	12q12
Locus type	gene with protein product
Status	Approved
Aliases	HMIT
Ensembl gene	ENSG00000151229
Ensembl biotype	protein_coding
OMIM	611036
Entrez	114134

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 6 protein_coding, 2 retained_intron

ENST00000280871, ENST00000380858, ENST00000465517, ENST00000505338, ENST00000858171, ENST00000858172, ENST00000858173, ENST00000957640

RefSeq mRNA: 1 — MANE Select: NM_052885 NM_052885

CCDS: CCDS8736

Canonical transcript exons

ENST00000280871 — 10 exons

Exon	Start	End
ENSE00000998418	40105253	40106081
ENSE00001098382	40028301	40028509
ENSE00001098384	40048051	40048210
ENSE00001182811	39764460	39764612
ENSE00001182813	39764737	39764858
ENSE00001182822	39871798	39871961
ENSE00001182824	39951257	39951365
ENSE00001228394	39830103	39830228
ENSE00001929605	39755025	39760252
ENSE00003664771	39864762	39864882

Expression profiles

Bgee: expression breadth ubiquitous, 247 present calls, max score 99.36.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 6.4316 / max 79.5867, expressed in 1577 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
130462	6.1483	1565
130461	0.2833	119

Top tissues by expression

253 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lateral nuclear group of thalamus	UBERON:0002736	99.36	gold quality
substantia nigra pars reticulata	UBERON:0001966	98.96	gold quality
endothelial cell	CL:0000115	98.14	gold quality
substantia nigra pars compacta	UBERON:0001965	98.11	gold quality
Brodmann (1909) area 23	UBERON:0013554	96.98	gold quality
Brodmann (1909) area 46	UBERON:0006483	96.95	gold quality
lateral globus pallidus	UBERON:0002476	95.92	gold quality
superior frontal gyrus	UBERON:0002661	95.09	gold quality
entorhinal cortex	UBERON:0002728	94.84	gold quality
middle temporal gyrus	UBERON:0002771	94.83	gold quality
buccal mucosa cell	CL:0002336	94.82	gold quality
postcentral gyrus	UBERON:0002581	94.53	gold quality
parietal lobe	UBERON:0001872	94.07	gold quality
epithelial cell of pancreas	CL:0000083	92.50	gold quality
ileal mucosa	UBERON:0000331	91.97	gold quality
mucosa of sigmoid colon	UBERON:0004993	91.82	gold quality
heart right ventricle	UBERON:0002080	91.79	gold quality
colonic mucosa	UBERON:0000317	91.59	gold quality
caput epididymis	UBERON:0004358	91.37	gold quality
occipital lobe	UBERON:0002021	91.31	gold quality
islet of Langerhans	UBERON:0000006	91.29	gold quality
jejunal mucosa	UBERON:0000399	91.11	gold quality
primary visual cortex	UBERON:0002436	91.06	gold quality
globus pallidus	UBERON:0001875	91.00	gold quality
medial globus pallidus	UBERON:0002477	90.98	gold quality
adrenal tissue	UBERON:0018303	90.61	gold quality
ventral tegmental area	UBERON:0002691	89.89	gold quality
cardiac muscle of right atrium	UBERON:0003379	88.15	gold quality
superior vestibular nucleus	UBERON:0007227	87.87	gold quality
renal medulla	UBERON:0000362	87.66	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-HCAD-25	yes	8.39
E-ANND-3	yes	5.57

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): E2F4

miRNA regulators (miRDB)

345 targeting SLC2A13, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-518D-5P	100.00	67.51	979
HSA-MIR-518E-5P	100.00	67.66	954
HSA-MIR-518F-5P	100.00	67.51	979
HSA-MIR-519A-5P	100.00	67.66	954
HSA-MIR-519B-5P	100.00	67.66	954
HSA-MIR-519C-5P	100.00	67.66	954
HSA-MIR-520C-5P	100.00	67.51	979
HSA-MIR-522-5P	100.00	67.66	954
HSA-MIR-523-5P	100.00	67.66	954
HSA-MIR-526A-5P	100.00	67.51	979
HSA-MIR-1193	100.00	65.93	529
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-5011-5P	100.00	83.46	5820

Literature-anchored findings (GeneRIF, showing 5)

• genetic alterations of TSPAN14, SLC2A13 and PHF20 could play a role in non-small-cell lung cancer promotion (PMID:19473719)
• HMIT is primarily a neuronal transporter widely expressed in the rat and human brain, with particularly high levels in the hippocampus and cortex, as shown by immunohistochemistry. (PMID:19607714)
• SLC2A13 is a novel gamma-secretase associated protein that regulates amyloid beta production without affecting Notch cleavage. (PMID:26094765)
• Our study revealed that both BDKRB2 and TENM2 genetic polymorphisms were interrogated in relation to anti-tuberculosis drug induced liver injury (ATDILI) susceptibility and some laboratory indicators in the Western Chinese Han population, shedding a new light on exploring novel biomarkers and targets for ATDILI. (PMID:31689868)
• The Solute Carrier Family 2 Genes Are Potential Prognostic Biomarkers in Acute Myeloid Leukemia. (PMID:31918632)

Cross-species orthologs

38 orthologs

Organism	Symbol	Gene ID
danio_rerio	slc2a13b	ENSDARG00000076899
danio_rerio	SLC2A13	ENSDARG00000087867
mus_musculus	Slc2a13	ENSMUSG00000036298
rattus_norvegicus	Slc2a13	ENSRNOG00000015741
drosophila_melanogaster	Glut3	FBGN0015230
drosophila_melanogaster	sut4	FBGN0028560
drosophila_melanogaster	sut3	FBGN0028561
drosophila_melanogaster	sut2	FBGN0028562
drosophila_melanogaster	sut1	FBGN0028563
drosophila_melanogaster	CG4607	FBGN0029932
drosophila_melanogaster	CG15406	FBGN0031517
drosophila_melanogaster	CG8837	FBGN0031520
drosophila_melanogaster	CG3285	FBGN0031522
drosophila_melanogaster	CG15408	FBGN0031523
drosophila_melanogaster	CG7882	FBGN0033047
drosophila_melanogaster	Tret1-2	FBGN0033644
drosophila_melanogaster	CG8249	FBGN0034045
drosophila_melanogaster	CG6484	FBGN0034247
drosophila_melanogaster	nebu	FBGN0036316
drosophila_melanogaster	CG14606	FBGN0037485
drosophila_melanogaster	CG14605	FBGN0037486
drosophila_melanogaster	CG6901	FBGN0038414
drosophila_melanogaster	CG17929	FBGN0038415
drosophila_melanogaster	CG17930	FBGN0038416
drosophila_melanogaster	Tret1-1	FBGN0050035
drosophila_melanogaster	CG33281	FBGN0053281
drosophila_melanogaster	CG33282	FBGN0053282
caenorhabditis_elegans		WBGENE00010684
caenorhabditis_elegans		WBGENE00010811
caenorhabditis_elegans		WBGENE00012536
caenorhabditis_elegans		WBGENE00013074
caenorhabditis_elegans		WBGENE00016431
caenorhabditis_elegans		WBGENE00017382
caenorhabditis_elegans		WBGENE00019547
caenorhabditis_elegans		WBGENE00019548
caenorhabditis_elegans		WBGENE00019549
caenorhabditis_elegans		WBGENE00019550
caenorhabditis_elegans		WBGENE00043980

Paralogs (13): SLC2A3 (ENSG00000059804), SLC2A9 (ENSG00000109667), SLC2A1 (ENSG00000117394), SLC2A11 (ENSG00000133460), SLC2A8 (ENSG00000136856), SLC2A5 (ENSG00000142583), SLC2A12 (ENSG00000146411), SLC2A6 (ENSG00000160326), SLC2A2 (ENSG00000163581), SLC2A14 (ENSG00000173262), SLC2A4 (ENSG00000181856), SLC2A7 (ENSG00000197241), SLC2A10 (ENSG00000197496)

Protein

Protein identifiers

Proton myo-inositol cotransporter — Q96QE2 (reviewed: Q96QE2)

Alternative names: H(+)-myo-inositol symporter, Solute carrier family 2 member 13

All UniProt accessions (2): Q96QE2, E9PE47

UniProt curated annotations — full annotation on UniProt →

Function. H(+)-myo-inositol cotransporter. Can also transport related stereoisomers.

Subcellular location. Cell membrane.

Tissue specificity. Predominantly expressed in the brain.

Post-translational modifications. Glycosylated.

Induction. Induced by hyperosmotic stress.

Similarity. Belongs to the major facilitator superfamily. Sugar transporter (TC 2.A.1.1) family.

RefSeq proteins (1): NP_443117* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003663	Sugar/inositol_transpt	Family
IPR005828	MFS_sugar_transport-like	Family
IPR005829	Sugar_transporter_CS	Conserved_site
IPR020846	MFS_dom	Domain
IPR036259	MFS_trans_sf	Homologous_superfamily
IPR050814	Myo-inositol_Transporter	Family

Pfam: PF00083

Catalyzed reactions (Rhea), 1 shown:

• myo-inositol(out) + H(+)(out) = myo-inositol(in) + H(+)(in) (RHEA:60364)

UniProt features (34 total): topological domain 13, transmembrane region 12, modified residue 5, glycosylation site 3, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96QE2-F1	80.34	0.48

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (5): 6, 47, 50, 640, 645

Glycosylation sites (3): 433, 458, 485

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-429593	Inositol transporters
R-HSA-382551	Transport of small molecules
R-HSA-425366
R-HSA-425407	SLC-mediated transmembrane transport

MSigDB gene sets: 203 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_BRAIN_TUMORAL_MACROPHAGE_DN, GOBP_CIRCULATORY_SYSTEM_PROCESS, GOBP_POSITIVE_REGULATION_OF_AMIDE_METABOLIC_PROCESS, chr12q12, TGACCTY_ERR1_Q2, GOBP_ORGANIC_HYDROXY_COMPOUND_TRANSPORT, GTGCCTT_MIR506, GOBP_REGULATION_OF_AMYLOID_PRECURSOR_PROTEIN_CATABOLIC_PROCESS, GOBP_AMIDE_METABOLIC_PROCESS, GOMF_PROTON_TRANSMEMBRANE_TRANSPORTER_ACTIVITY, GOCC_APICAL_PLASMA_MEMBRANE, AACTTT_UNKNOWN, GOBP_REGULATION_OF_AMIDE_METABOLIC_PROCESS, GOBP_AMYLOID_PRECURSOR_PROTEIN_METABOLIC_PROCESS, GOCC_NEURON_PROJECTION

GO Biological Process (4): myo-inositol transport (GO:0015798), transmembrane transport (GO:0055085), transport across blood-brain barrier (GO:0150104), positive regulation of amyloid-beta formation (GO:1902004)

GO Molecular Function (6): protease binding (GO:0002020), myo-inositol transmembrane transporter activity (GO:0005365), myo-inositol:proton symporter activity (GO:0005366), ATPase binding (GO:0051117), protein binding (GO:0005515), transmembrane transporter activity (GO:0022857)

GO Cellular Component (11): cytoplasm (GO:0005737), Golgi apparatus (GO:0005794), plasma membrane (GO:0005886), membrane (GO:0016020), apical plasma membrane (GO:0016324), growth cone (GO:0030426), organelle membrane (GO:0031090), cell projection (GO:0042995), cell body (GO:0044297), cell periphery (GO:0071944), astrocyte end-foot (GO:0097450)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
SLC-mediated transmembrane transport	1
Transport of small molecules	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	5
enzyme binding	2
membrane	2
organic hydroxy compound transport	1
transport	1
cellular process	1
vascular transport	1
amyloid-beta formation	1
regulation of amyloid-beta formation	1
positive regulation of amyloid precursor protein catabolic process	1
polyol transmembrane transporter activity	1
myo-inositol transport	1
myo-inositol transmembrane transporter activity	1
solute:proton symporter activity	1
binding	1
transporter activity	1
transmembrane transport	1
intracellular anatomical structure	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
cell periphery	1
apical part of cell	1
plasma membrane region	1
site of polarized growth	1
distal axon	1
membrane-bounded organelle	1
astrocyte projection	1

Protein interactions and networks

STRING

2016 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLC2A13	SLC5A3	P53794	725
SLC2A13	H7C1H1	H7C1H1	678
SLC2A13	SLC5A11	Q8WWX8	593
SLC2A13	TMEM117	Q9H0C3	516
SLC2A13	ISYNA1	Q9NPH2	477
SLC2A13	MIOX	Q9UGB7	467
SLC2A13	FRMPD1	Q5SYB0	449
SLC2A13	SLC50A1	Q9BRV3	449
SLC2A13	KBTBD12	Q3ZCT8	440
SLC2A13	SLC5A1	P13866	435
SLC2A13	TMEM51	Q9NW97	434
SLC2A13	CPNE5	Q9HCH3	425
SLC2A13	TMEM161B	Q8NDZ6	424
SLC2A13	RAB28	P51157	422
SLC2A13	SLC5A4	Q9NY91	413

IntAct

22 interactions, top by confidence:

A	B	Type	Score
CYP4F2	SLC2A13	psi-mi:“MI:0915”(physical association)	0.560
SLC2A13	RIC8A	psi-mi:“MI:0915”(physical association)	0.560
	SLC2A13	psi-mi:“MI:0915”(physical association)	0.560
PLP2	SLC2A13	psi-mi:“MI:0915”(physical association)	0.560
SLC2A13	OPTN	psi-mi:“MI:0915”(physical association)	0.560
NCR3LG1	PEDS1	psi-mi:“MI:0914”(association)	0.350
SLC2A13	RIOK3	psi-mi:“MI:0914”(association)	0.350
FECH	POTEF	psi-mi:“MI:0914”(association)	0.350
SLC2A13	CLGN	psi-mi:“MI:0914”(association)	0.350
PSEN1	SLC2A13	psi-mi:“MI:2364”(proximity)	0.270
CYP4F2	SLC2A13	psi-mi:“MI:0915”(physical association)	0.000
SLC2A13	RIC8A	psi-mi:“MI:0915”(physical association)	0.000
PLP2	SLC2A13	psi-mi:“MI:0915”(physical association)	0.000
	SLC2A13	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (29): SLC2A13 (Affinity Capture-RNA), SLC2A13 (Two-hybrid), RIC8A (Two-hybrid), CYP4F2 (Two-hybrid), FXYD6-FXYD2 (Two-hybrid), SLC2A13 (Proximity Label-MS), SLC2A13 (Proximity Label-MS), SLC2A13 (Affinity Capture-MS), BLK (Affinity Capture-MS), RIOK3 (Affinity Capture-MS), ATG9A (Affinity Capture-MS), SLC2A13 (PCA), SLC2A13 (Affinity Capture-MS), ABCB7 (Affinity Capture-MS), AP3M1 (Affinity Capture-MS)

ESM2 similar proteins: A4FV52, A6QLI1, O00476, O00624, O61369, O62786, P34272, P34644, P38142, Q03567, Q05B21, Q10046, Q14916, Q1L8X9, Q21455, Q28722, Q2QWW7, Q32LF0, Q3TXX4, Q3UHK1, Q5NCM1, Q5SZA1, Q5W8I7, Q5W8I8, Q61983, Q62634, Q62795, Q66KG0, Q6INC8, Q7TSF2, Q7ZX53, Q8BFU8, Q8BLE7, Q8NDX2, Q921A2, Q95R48, Q961J5, Q96QE2, Q9C757, Q9FKV1

Diamond homologs: A0A0H2VG78, A0A1D8PH98, A9ZSY3, B4HNS1, B4QBN3, C0SPB2, F1R0H0, J9VHZ4, O04249, O23492, O34718, O52733, O62786, O62787, O65413, P0AE24, P0AE25, P0AEP1, P0AEP2, P0AGF4, P0AGF5, P11166, P11167, P11169, P12336, P13355, P14246, P15686, P15729, P17809, P23586, P27674, P30605, P30606, P32037, P39924, P45598, P46333, P46896, P47185

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

37 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	33
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

3444 predictions. Top by Δscore:

Variant	Effect	Δscore
12:39760071:T:TA	donor_gain	1.0000
12:39760072:C:A	donor_gain	1.0000
12:39760101:C:CA	donor_gain	1.0000
12:39760135:AG:A	donor_gain	1.0000
12:39760162:T:A	donor_gain	1.0000
12:39764454:TCTTA:T	donor_loss	1.0000
12:39764455:CTTA:C	donor_loss	1.0000
12:39764456:TTA:T	donor_loss	1.0000
12:39764457:TACCA:T	donor_loss	1.0000
12:39764458:A:AC	donor_gain	1.0000
12:39764458:A:AT	donor_loss	1.0000
12:39764459:C:CA	donor_loss	1.0000
12:39764459:C:CC	donor_gain	1.0000
12:39764608:CATTC:C	acceptor_gain	1.0000
12:39764610:TTC:T	acceptor_gain	1.0000
12:39764610:TTCC:T	acceptor_loss	1.0000
12:39764611:TCCT:T	acceptor_loss	1.0000
12:39764612:CCTG:C	acceptor_loss	1.0000
12:39764613:C:CC	acceptor_gain	1.0000
12:39764614:T:A	acceptor_loss	1.0000
12:39951255:A:AC	donor_gain	1.0000
12:39951256:C:CC	donor_gain	1.0000
12:39951371:T:TC	acceptor_gain	1.0000
12:40015750:A:T	acceptor_gain	1.0000
12:40028298:TA:T	donor_loss	1.0000
12:40028505:TGTAC:T	acceptor_gain	1.0000
12:40028507:TAC:T	acceptor_gain	1.0000
12:40028508:ACCT:A	acceptor_loss	1.0000
12:40028509:CCTG:C	acceptor_loss	1.0000
12:40028510:C:CC	acceptor_gain	1.0000

AlphaMissense

4179 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:39764549:C:T	G544E	1.000
12:40028440:G:C	S262R	1.000
12:40028440:G:T	S262R	1.000
12:40028442:T:G	S262R	1.000
12:40048053:C:A	W238C	1.000
12:40048053:C:G	W238C	1.000
12:40048055:A:G	W238R	1.000
12:40048055:A:T	W238R	1.000
12:39764491:A:C	F563L	0.999
12:39764491:A:T	F563L	0.999
12:39764493:A:G	F563L	0.999
12:39764512:A:C	N556K	0.999
12:39764512:A:T	N556K	0.999
12:39764550:C:G	G544R	0.999
12:39764550:C:T	G544R	0.999
12:39764554:A:C	S542R	0.999
12:39764554:A:T	S542R	0.999
12:39764556:T:G	S542R	0.999
12:39764557:T:A	R541S	0.999
12:39764557:T:G	R541S	0.999
12:39764558:C:G	R541T	0.999
12:39764574:A:C	Y536D	0.999
12:39764576:A:T	I535K	0.999
12:39764583:A:G	S533P	0.999
12:39764584:A:C	N532K	0.999
12:39764584:A:T	N532K	0.999
12:39764595:A:G	W529R	0.999
12:39764595:A:T	W529R	0.999
12:39764612:C:T	G523E	0.999
12:39871805:A:C	S397R	0.999

dbSNP variants (sampled 300 via entrez): RS1000003797 (12:40032605 G>C,T), RS1000004098 (12:39955604 A>C), RS1000015162 (12:39870238 A>G), RS1000027485 (12:40051458 T>C), RS1000051362 (12:39919241 T>C), RS1000056435 (12:39940028 C>T), RS1000065459 (12:40106111 C>G,T), RS1000069591 (12:40052500 T>A), RS1000079975 (12:39913863 T>TA), RS1000081012 (12:39785237 C>G), RS1000082162 (12:40004206 T>C), RS1000082720 (12:39962153 A>C,G), RS1000084068 (12:39845009 T>C), RS1000086472 (12:39956982 T>C), RS1000108457 (12:39940410 A>T)

Disease associations

OMIM: gene MIM:611036 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

12 associations (top):

Study	Trait	p-value
GCST001430_13	Parkinson’s disease	1.000000e-06
GCST002049_2	Sleep quality	3.000000e-06
GCST002052_1	Insomnia	2.000000e-06
GCST002097_37	Coronary artery calcification	4.000000e-06
GCST003518_35	Daytime sleep phenotypes	8.000000e-07
GCST003922_3	Parkinson’s disease	8.000000e-12
GCST004131_46	Inflammatory bowel disease	3.000000e-15
GCST004132_23	Crohn’s disease	6.000000e-20
GCST008438_4	Alzheimer’s disease in hypertension	3.000000e-06
GCST009262_5	Putamen volume	3.000000e-06
GCST009526_3	Disability (impaired activities of daily living)	9.000000e-06
GCST010991_15	Parkinson’s disease	7.000000e-26

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0007876	insomnia measurement
EFO:0004723	coronary artery calcification
EFO:0007828	daytime rest measurement
EFO:0008451	activities of daily living score measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — Proton-coupled inositol transporter

CTD chemical–gene interactions

44 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression, decreases methylation	9
trichostatin A	affects cotreatment, increases expression	3
Benzo(a)pyrene	decreases expression, increases methylation	3
bisphenol A	increases expression, affects cotreatment, increases methylation	2
(+)-JQ1 compound	increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
aristolochic acid I	decreases expression	1
GSK-J4	increases expression	1
FR900359	decreases phosphorylation	1
geldanamycin	increases expression	1
triphenyl phosphate	affects expression	1
terbufos	decreases methylation	1
cinnamaldehyde	increases expression	1
beta-lapachone	decreases expression	1
N-(1,3-dimethylbutyl)-N’-phenyl-1,4-phenylenediamine	affects response to substance	1
manganese chloride	increases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	increases reaction, affects binding	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	increases expression, increases response to substance	1
jinfukang	affects cotreatment, decreases expression	1
Resveratrol	increases expression, affects cotreatment	1
Fulvestrant	increases methylation, affects cotreatment	1
Vorinostat	increases expression	1
Acetaminophen	increases expression	1
Air Pollutants	affects expression, increases abundance	1
Cisplatin	affects cotreatment, decreases expression	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D4L6	HCT116-SLC2A13-KO-c10	Cancer cell line	Male
CVCL_D4L7	HCT116-SLC2A13-KO-c7	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.